Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Gastric Cancer

OncLive Staff
The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application for Lonsurf (TAS-102; trifluridine/tipiracil) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Jason Harris
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
Brielle Urciuoli
While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.
Beth Fand Incollingo
But just what information is most useful to patients with NETs, and where are the gaps in the educational and supportive resources to which they have access? A study – presented at the Gastrointestinal Cancers Symposium on Jan. 19, in San Francisco – explored just that.
Jason M. Broderick
Keytruda (pembrolizumab) was granted FDA approval for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more lines of chemotherapy and are PD-L1-positive.
Brielle Urciuoli
Patients with advanced gastric cancer tend to use their health care resources more often and have a worse quality of life than those without the disease
Silas Inman
Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
Jason Harris
Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.
Gina Columbus
Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other